OA15.04 Structural basis of neutralizing antibodies targeting the CD4-binding site and fusion peptide elicited by immunization with heterologous HIV-1 Env in NHPOral Abstract SessionNovel vaccine and other prevention approaches
OA15.05LB Cross-reactivity between HIV-1 bnAbs and parasite glycansOral Abstract SessionNovel vaccine and other prevention approaches
OA16.01 Trends in incidence of bacterial sexually transmitted infections among gay and bisexual men using PrEP in AustraliaOral Abstract SessionImplementation science, including structural interventions, PrEP & VMMC
OA16.02 For MSM attending sexual health clinics in England, rates of new HIV infections decreased and rates of new rectal GC diagnosis increased between 2010-2018Oral Abstract SessionEpidemiology of HIV
OA16.03 Comparing Applicator vs. “As Lubricant” Delivery of Rectal Dapivirine Gel (MTN-033)Oral Abstract SessionCOVID research: Applying lessons from HIV prevention to SARS CoV-2
OA16.04 Phase 1 safety and pharmacokinetic study of candidate rectal microbicide PC-1005 rectal gel (MIV-150/zinc acetate /carrageenan) in HIV-1 seronegative adults (MTN-037)Oral Abstract SessionDelivery technologies: novel approaches, formulation and multi-purpose
OA16.05 A randomized, double blind, placebo-controlled, phase 1 safety and pharmacokinetic study of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults (MTN-026)Oral Abstract SessionPharmacology/PK and PD studies
OA17.01 Eliciting participant feedback in focus group discussions to strengthen the implementation of a HIV prevention studyOral Abstract SessionCommunity engagement in prevention research
OA17.02 A synergistic model of engagement: the ECHO Global Community Advisory Group and HC-HIV Advocacy Working GroupOral Abstract SessionCommunity engagement in prevention research
OA17.03 The value of outside engagement-civil society led engagement in PopARTOral Abstract SessionCommunity engagement in prevention research
seek-warrow-warrow-eseek-e151 - 160 of 444 items